ArticleJAMA neurology2019
Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years.
Article in JAMA neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 97 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Alzheimer's Clinical Trial Consortium for Down Syndrome (ACTC-DS) Trial-Ready Cohort - Down Syndrome (TRC-DS)
Neuropsychological Evaluation in Intellectual Disability
Phase 1B Trial on Escalating Doses of Memantine in Down Syndrome
Who cites it
97 citing papers in PubMed, 4 syntheses or guidelines pooled it, 168 citations in OpenAlex.
- Early Markers for Dementia in the Intellectual Disability Population: A Systematic Literature Review.Journal of applied research in intellectual disabilities : JARID · 2025Pooled it
- A meta-analysis and systematic review of interventions to prevent or treat cognitive decline related to Alzheimer's disease in adults with Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Blood-based biomarkers for Alzheimer's disease in Down syndrome: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome.JAMA network open · 2022Pooled it
- The association of increased body mass index on cardiorespiratory fitness, physical activity, and cognition in adults with down syndrome.Disability and health journal · 2023Trial
- Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial.JAMA neurology · 2022Trial
- Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.Expert review of neurotherapeutics · 2026Review
- Progressive myoclonus epilepsy in Down syndrome with Alzheimer's disease: An 11-year longitudinal study and proposed diagnostic red flags.Epilepsia open · 2026Article
- Death in People with Down syndrome: Mortality statistics and novel predictors in US Medicaid and Medicare enrolled adults.medRxiv : the preprint server for health sciences · 2026Article
- The tau biomarker cascade is condensed in Down syndrome compared with sporadic Alzheimer's disease.Brain : a journal of neurology · 2026Article
- (Alzheimer's) dementia in adults with Down syndrome in Germany: Administrative prevalence based on a claims data analysis.Journal of Alzheimer's disease : JAD · 2026Article
- Structural MRI across lifespan reveals differential thalamic trajectories in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Determinants of Healthcare Costs in Individuals With Down Syndrome: A Systematic Review.Health science reports · 2026Review
- Cerebrospinal fluid and frontal cortex TMPRSS2 and ACE2 protein levels differ in Down syndrome and Alzheimer's disease.Acta neuropathologica communications · 2026Article
- Use of anti-amyloid-β monoclonal antibodies in persons with Down syndrome Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Caregivers' Perspectives on Medical Management and Its Helpfulness in Down Syndrome.American journal of medical genetics. Part A · 2026Article
- Equitable inclusion of people with disabilities in clinical trials: a scoping review.BMJ open · 2026Article
- Factors impacting survival in individuals with Down syndrome-associated Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Caregiver Interviews Regarding Health in Down Syndrome.American journal of medical genetics. Part A · 2026Observational
- Predicting low premorbid cognitive ability with social determinants: A machine learning approach.JAR life · 2026Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
Abstract
Importance: This work quantifies the fatal burden of dementia associated with Alzheimer disease in individuals with Down syndrome (DS). Objective: To explore the association of dementia associated with Alzheimer disease with mortality and examine factors associated with dementia in adults with DS. Design, Settings and Participants: Prospective longitudinal study in a community setting in England. Data collection began March 29, 2012. Cases were censored on December 13, 2017. The potential sample consisted of all adults 36 years and older from the London Down Syndrome Consortium cohort with 2 data times and dementia status recorded (N = 300); 6 withdrew from study, 28 were lost to follow-up, and 55 had a single data collection point at time of analysis. The final sample consisted of 211 participants, with 503.92 person-years' follow-up. Exposures: Dementia status, age, sex, APOE genotype, level of intellectual disability, health variables, and living situation. Main Outcomes and Measures: Crude mortality rates, time to death, and time to dementia diagnosis with proportional hazards of predictors. Results: Of the 211 participants, 96 were women (45.5%) and 66 (31.3%) had a clinical dementia diagnosis. Twenty-seven participants (11 female; mean age at death, 56.74 years) died during the study period. Seventy percent had dementia. Crude mortality rates for individuals with dementia (1191.85 deaths per 10 000 person-years; 95% CI, 1168.49-1215.21) were 5 times higher than for those without (232.22 deaths per 10 000 person-years; 95% CI, 227.67-236.77). For those with dementia, APOE ε4 carriers had a 7-fold increased risk of death (hazard ratio [HR], 6.91; 95% CI, 1.756-27.195). For those without dementia, epilepsy with onset after age 36 years was associated with mortality (HR, 9.66; 95% CI, 1.59-58.56). APOE ε4 carriers (HR, 4.91; 95% CI, 2.53-9.56), adults with early-onset epilepsy (HR, 3.61; 95% CI, 1.12-11.60), multiple health comorbidities (HR, 1.956; 95% CI, 1.087-3.519), and those living with family (HR, 2.14; 95% CI, 1.08-4.20) received significantly earlier dementia diagnoses. Conclusions and Relevance: Dementia was associated with mortality in 70% of older adults with DS. APOE ε4 carriers and/or people with multiple comorbid health conditions were at increased risk of dementia and death, highlighting the need for good health care. For those who died without a dementia diagnosis, late-onset epilepsy was the only significant factor associated with death, raising questions about potentially undiagnosed dementia cases in this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.